Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,525 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,876 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00590681 | Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT00905060 | HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM(HeatShock) | completed | Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | completed | Phase 2 / Phase 3 | 88 | Sahlgrenska University HospitalOTHER | 2 | Mar 18, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02147028 | Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases(HIPPO) | completed | Phase 2 | 23 | University College, LondonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03033524 | Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma | completed | Phase 2 | 12 | PharmAbcineINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT01414738 | Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases | completed | Phase 2 | 50 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01740258 | Bevacizumab Beyond Progression (BBP)(BBP) | completed | Phase 2 | 68 | Duke UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02209948 | Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. | completed | Phase 2 | 166 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT01967576 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02337491 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | completed | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02197637 | Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma(OVIMA-1210) | completed | Phase 2 | 39 | Centre Oscar LambretOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT01635283 | Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma | completed | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00590954 | Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01467986 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma(RIST-rNB-2011) | completed | Phase 2 | 130 | University of RegensburgOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00883688 | Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01390948 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 14 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00179920 | Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma | completed | Phase 2 | 30 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02540161 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 43 | Annick DesjardinsOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00823459 | Everolimus in Treating Patients With Recurrent Low-Grade Glioma | completed | Phase 2 | 58 | Susan ChangOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT00795665 | Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma | completed | Phase 2 | 7 | University of California, DavisOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01140568 | Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | completed | Phase 2 | 38 | David Piccioni, M.D., Ph.DOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma(ALECSAT) | completed | Phase 2 | 62 | CytoVac A/SINDUSTRY | 1 | Apr 30, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT03936426 | Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ | completed | Phase 1 / Phase 2 | 5 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Apr 20, 2020 | clinicaltrials |
| NCT01635907 | Dovitinib in Neuroendocrine Tumors | completed | Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02342379 | TH-302 in Combination With Bevacizumab for Glioblastoma | completed | Phase 2 | 35 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma(PEPI) | completed | Phase 2 | 13 | Baylor College of MedicineOTHER | 1 | Mar 27, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 30, 2021source: clinicaltrials